top of page
About Us
Mablink Bioscience aims to dramatically improve the efficacy of ADC against cancer
Our ambition
is to build a pipeline of novel antibody-drug conjugates with the potential to transform the paradigm in solid tumors treatment over the next 4 years.
Mablink’s proprietary hydrophilic drug-linker technology, PSARLink™, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability.
Our leadership
Our team is comprised of experts in biomedical engineering, medicinal organic chemistry, bioconjugation, pharmacology, antibody-drug conjugates, target validation and antibody development, and drug development with successful experience in development of innovative oncology immunotherapies.
Our outstanding journey
2019
Publication of outstanding
PSARlink™ PoC results
€1.5M (iLAB...)
Innovation grants
2022
€31M Series A co-led by Sofinnova Partners & MxEP
3rd patent filed
2018
Inception:
Core patent filed
Company creation (December)
2021
€4M seed funding
Licensing deal with Emergence TX
Publication PSARlink™ + exatecan
2nd patent filed
2023
Promising Data for lead candidate MBK-103 at AACR 2023
2024
First-in-human trial with MBK-103 planned
Our investors
bottom of page